Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment… Read more
Agios Pharmaceuticals, Inc. (0HB0) - Total Liabilities
Latest total liabilities as of September 2025: $101.38 Million USD
Based on the latest financial reports, Agios Pharmaceuticals, Inc. (0HB0) has total liabilities worth $101.38 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Agios Pharmaceuticals, Inc. - Total Liabilities Trend (2012–2024)
This chart illustrates how Agios Pharmaceuticals, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Agios Pharmaceuticals, Inc. Competitors by Total Liabilities
The table below lists competitors of Agios Pharmaceuticals, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
John Wiley & Sons B
NYSE:WLYB
|
USA | $1.73 Billion |
|
REA Group Limited
PINK:RPGRY
|
USA | $872.93 Million |
|
Nanjing Yunhai Special Metals Co Ltd
SHE:002182
|
China | CN¥8.17 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.30 Billion |
|
Sejahteraraya Anugrahjaya Tbk
JK:SRAJ
|
Indonesia | Rp6.19 Trillion |
|
NRW Holdings Ltd
AU:NWH
|
Australia | AU$1.41 Billion |
|
NAPCO Security Technologies Inc
NASDAQ:NSSC
|
USA | $28.01 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Agios Pharmaceuticals, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.82 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Agios Pharmaceuticals, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Agios Pharmaceuticals, Inc. (2012–2024)
The table below shows the annual total liabilities of Agios Pharmaceuticals, Inc. from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $122.24 Million | -3.06% |
| 2023-12-31 | $126.10 Million | -8.56% |
| 2022-12-31 | $137.90 Million | -5.39% |
| 2021-12-31 | $145.76 Million | -67.86% |
| 2020-12-31 | $453.45 Million | +81.23% |
| 2019-12-31 | $250.21 Million | +46.39% |
| 2018-12-31 | $170.92 Million | -28.45% |
| 2017-12-31 | $238.89 Million | -8.30% |
| 2016-12-31 | $260.50 Million | +247.58% |
| 2015-12-31 | $74.95 Million | +22.68% |
| 2014-12-31 | $61.09 Million | +65.42% |
| 2013-12-31 | $36.93 Million | +5.17% |
| 2012-12-31 | $35.11 Million | -- |